Prescribing a Receivables Ratio for Sun Pharma Custom Case Solution & Analysis

Evidence Brief: Sun Pharma Receivables Management

1. Financial Metrics

• Days Sales Outstanding (DSO): The core metric under scrutiny. Standard industry benchmarks for generic pharmaceutical distributors range between 60 to 90 days.
• Operating Cash Flow: Heavily impacted by the timing of collections from large institutional buyers.
• Accounts Receivable (AR) Aging: Significant concentration in the 90+ day bucket, indicating collection friction.
• Profit Margins: Operating margins are compressed by the cost of carrying excess working capital.

2. Operational Facts

• Customer Base: Fragmented mix of independent pharmacies, large retail chains, and government institutions.
• Credit Policy: Current policy is decentralized; local sales managers possess authority to extend payment terms to secure volume.
• Collection Process: Manual reconciliation process prone to administrative delays and disputes over invoice accuracy.

3. Stakeholder Positions

• Sales Department: Advocates for flexible credit terms as a primary tool to maintain volume and market share against aggressive generic competitors.
• Finance/Treasury: Prioritizes liquidity and seeks a standardized, aggressive DSO reduction target to improve cash conversion cycles.
• Institutional Buyers: Utilize their size to dictate payment terms, often pushing payments beyond 120 days.

4. Information Gaps

• Specific cost of capital for Sun Pharma.
• Granular data on the correlation between extended payment terms and actual incremental volume gain.
• Detailed breakdown of bad debt write-offs by customer segment.

Strategic Analysis

Core Strategic Question: How can Sun Pharma optimize its working capital while maintaining market share in a commoditized generic drug market where credit terms function as a competitive lever?

Structural Analysis:

• Value Chain: The current model treats credit as a sales subsidy. This obscures the true profitability of individual accounts by failing to account for the cost of carrying receivables.
• Porter Five Forces: Buyer power is high due to the commoditized nature of generic drugs. Suppliers (Sun) have limited ability to enforce terms without risking volume loss to competitors who will offer the same terms.

Strategic Options:

• Option 1: Hard Standardized Policy. Impose a 60-day maximum on all accounts. Trade-off: Immediate cash flow improvement but high risk of losing volume to competitors with more flexible terms. Resource: Significant change management and sales compensation restructuring.
• Option 2: Segmented Tiered Terms. Align credit terms with customer profitability and size. Trade-off: Protects high-margin/high-volume accounts while tightening terms on smaller, high-risk accounts. Resource: Advanced credit scoring and data integration.
• Option 3: Financial Incentives for Early Payment. Implement a 2/10 net 30 model. Trade-off: Immediate liquidity boost, but creates margin erosion. Resource: High operational complexity in billing reconciliation.

Preliminary Recommendation: Option 2. Standardizing terms across a heterogeneous customer base is a strategic error. Sun Pharma must shift to risk-adjusted, segment-based credit terms.

Implementation Roadmap

Critical Path:

• Phase 1: Segment the customer base by profitability and payment history (Weeks 1-4).
• Phase 2: Redesign the sales commission structure to include a DSO/Collection component (Weeks 5-8).
• Phase 3: Pilot the new credit terms with the lowest-tier, highest-risk customers (Weeks 9-12).

Key Constraints:

• Sales Force Resistance: The team views credit as their primary tool; removing it without replacement incentives will trigger turnover.
• Systemic Limitations: Current billing systems lack the automated triggers to enforce tiered terms effectively.

Risk-Adjusted Strategy: Phase the rollout. Do not implement company-wide changes simultaneously. Use the pilot phase to quantify the actual volume loss versus the cash flow gain before applying the policy to key accounts.

Executive Review and BLUF

BLUF: Sun Pharma is currently financing its customers at the expense of its own liquidity. The company must stop using credit as a sales tool for low-margin accounts. My recommendation is to implement a tiered credit policy that ties payment terms to account profitability. If an account cannot adhere to a 60-day limit, it should be moved to a cash-on-delivery model or offloaded to a distributor. The current decentralized credit approval process is a governance failure that must be centralized under the CFO. This is an operational cleanup, not a market strategy shift.

Dangerous Assumption: The analysis assumes that current sales volume is profitable. It is highly probable that a significant percentage of current volume is actually value-destructive when the cost of capital and collection risk are factored in.

Unaddressed Risks:

• Competitive Aggression: Competitors may use this transition as a window to poach Sun’s key accounts by doubling down on extended credit.
• Operational Friction: The existing billing infrastructure is likely too manual to support a complex, tiered credit policy, leading to increased customer disputes.

Unconsidered Alternative: Factoring receivables. Instead of managing the credit risk internally, Sun should offload a portion of its receivables to a third-party financier. This moves the collection burden to an entity better equipped to handle it, albeit at a cost to margin.

Verdict: APPROVED FOR LEADERSHIP REVIEW.